Form 4 for IT Gartner
Accepted 2024-11-08 00:00:00 ET · period of report 2024-11-06 · accession 0001127602-24-026864 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-08 | 2024-11-06 | IT | HALL EUGENE A | COB, CEO, Dir | F - Tax | $536.90 | -14.5K | 1.16M | -1% | -$7.81M |
| D | 2024-11-08 | 2024-11-06 | IT | HALL EUGENE A | COB, CEO, Dir | M - OptEx | $180.64 | +49.5K | 1.19M | +4% | +$8.94M |
| D | 2024-11-08 | 2024-11-06 | IT | HALL EUGENE A | COB, CEO, Dir | D - Sale to Iss | $536.90 | -16.7K | 1.18M | -1% | -$8.94M |
| D | 2024-11-08 | 2024-11-06 | IT | HALL EUGENE A | COB, CEO, Dir | M - OptEx | $0.00 | -49.5K | 16.5K | -75% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-06 | F | D | 14,543 | $536.90 | 1,161,697 | D | — | — | (F3) Represents shares withheld for the payment of applicable income and payroll withholding taxes. |
| 2 | Common | Common Stock | 2024-11-06 | M | A | 49,490 | $180.64 | 1,192,891 | D | — | — | (F1) Represents shares acquired upon exercise of SARs. |
| 3 | Common | Common Stock | 2024-11-06 | D | D | 16,651 | $536.90 | 1,176,240 | D | — | — | (F2) Represents shares withheld that had an aggregate value, based on the market price on the date of exercise, substantially equal to the aggregate exercise price of the SARs. |
| 4 | Derivative | Stock Appreciation Rights | 2024-11-06 | M | D | 49,490 | $0.00 | 16,496 | D | $180.64 · 2022-02-10 to 2028-02-10 | 49,490 Common Stock | (F4) These SARs are part of an award that became exercisable in four substantially equal annual installments, commencing on February 10, 2022, and are fully exercisable. |